Pepdexpepdex
Stack
← All compounds

CBD

Cannabidiol · Cannabinoid (non-intoxicating)

Research reference only. Pepdex does not sell, supply or track this compound, and nothing here is guidance to use it — this page exists so the evidence and the risks are visible.

What it is

The non-intoxicating cannabinoid — sold in every format from oils to topical roll-ons, with one prescription form (Epidiolex) for rare epilepsies. Related entry: THC.

How it works

CBD is one of the two cannabinoids people know by name, and the one that does not produce intoxication. Unlike THC it barely binds the CB1 receptor, which is why it does not get you high. Beyond that, be honest about the mechanism: the approved product's label states its precise anticonvulsant mechanism in humans is UNKNOWN and does not appear to involve cannabinoid receptors. The serotonin, endocannabinoid-enzyme and ion-channel accounts in circulation are proposed or preclinical rather than the established human explanation — which is also why it is proposed for almost everything and demonstrated for almost nothing.

What human evidence shows

One genuinely proven indication: seizure reduction in specific epilepsy syndromes (the Epidiolex RCTs). Everything else — anxiety, sleep, pain, recovery — runs on small trials with mixed results, mostly at pharmaceutical doses rather than consumer-product ones.

The studies, one by one

  • STRONG for the narrow indication it is actually approved for: Epidiolex, a prescription CBD product, reduces seizure frequency in Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex. That is real, large randomised evidence at pharmaceutical amounts far above consumer products.
  • LIMITED for anxiety — some small trials report reductions, results are mixed, and the amounts studied are typically far higher than retail products contain.
  • NONE SHOWN for pain, sleep, inflammation or recovery in the sense consumer products are sold for. The trials either do not exist or do not support it.
  • The FDA has repeatedly found retail CBD products contain substantially more or less CBD than labelled, and some contain THC that is not declared — which matters for anyone drug-tested.
  • The prescription label carries more than enzyme elevations: warnings for potentially serious liver injury, sedation and somnolence, suicidal behaviour or ideation, and hypersensitivity. FDA also notes animal evidence of male reproductive toxicity and advises against use in pregnancy and breastfeeding. Liver risk is highest alongside valproate.

Half-life and how long it lasts

Poorly absorbed orally, with substantial first-pass metabolism, which is why the approved product uses amounts far above what retail products contain and why comparisons between them are not meaningful. It inhibits several liver enzymes including CYP3A4 and CYP2C19, giving it a genuinely broad interaction surface that its wellness positioning obscures.

Risks

Mild profile in trials (fatigue, GI upset, appetite change) with two caveats that matter here: documented liver-enzyme elevation at pharmaceutical doses, and real drug interactions via CYP450 — it inhibits the enzymes that clear many common medications. Market-integrity is the bigger issue: independent testing repeatedly finds products with wrong CBD content and detectable THC in "THC-free" items — relevant to anyone drug-tested.

Who should never touch it

  • Anyone taking medicines metabolised by CYP3A4 or CYP2C19 without checking with their prescriber
  • Anyone with liver disease, or taking valproate
  • Anyone subject to drug testing where undeclared THC would be a problem
  • Anyone pregnant or breastfeeding — FDA advises against it

Interactions worth knowing

  • Clobazam and valproate specifically — established in the epilepsy trials, with valproate carrying a liver-enzyme signal.
  • Any CYP3A4 or CYP2C19 substrate, a very long list including some blood thinners, antidepressants and immunosuppressants. Warfarin interaction is documented.
  • Alcohol and other sedatives, where drowsiness is additive.
  • Grapefruit-warning drugs as a rule of thumb: if a drug says avoid grapefruit, CBD is worth raising with the prescriber for the same reason.

What a clinician would watch

  • Any other medication you take — the enzyme inhibition is the most underappreciated thing about CBD, and it can raise levels of common prescriptions.
  • Liver symptoms, particularly for anyone on higher amounts or taking valproate.
  • Drug testing, if it applies to you — undeclared THC in retail products is documented.
  • Whether the product has a certificate of analysis, given repeated FDA findings of mislabelled content.

What stopping looks like

No withdrawal syndrome is described for CBD itself. The practical thing to know is the reverse direction: if it was raising the levels of another medicine through enzyme inhibition, stopping lets those levels fall again, which can matter for drugs with a narrow therapeutic range. Anyone taking it alongside a prescription should tell the prescriber when they stop, not only when they start.

Myth vs evidence

“CBD is non-psychoactive.”

It is non-INTOXICATING, which is different. It acts on the central nervous system and can cause drowsiness — those are psychoactive effects, just not a high.

“It cannot fail a drug test.”

Retail products have repeatedly been found to contain undeclared THC. Testing failures from CBD products are documented.

“It is harmless because it is natural and non-intoxicating.”

It inhibits major liver enzymes and can raise levels of other medicines. That is the most consequential and least discussed thing about it.

“The epilepsy approval proves it works for anxiety and pain.”

The approval is for three specific seizure disorders at pharmaceutical amounts. Nothing transfers automatically to other conditions at retail amounts.

Legal status

US: legally complicated. Hemp-derived CBD sits outside the CSA, but the FDA does not permit CBD as a dietary supplement or food additive, product rules vary by state, and federal hemp definitions are changing. Epidiolex is prescription-only. Sport rules generally allow CBD itself but athletes fail tests on THC contamination.

Research on this compound

Papers about this compound, not proof of the claims above. A title says what was studied, which is sometimes a negative result or a different question entirely.

  • Therapeutic potential of cannabidiol (CBD) in anxiety disorders: A systematic review and meta-analysis
    Psychiatry Res, 2024
  • Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis
    Exp Neurol, 2023

Evidence base

S15,059 research papers
established literature

Large human evidence base: several phase 3 or 4 trial reports, plus multiple meta-analyses or systematic reviews.

phase 3/4
14
randomised
456
reviews
322
human trials
630

Counts are of published papers, not distinct trials, and they nest rather than add up: PubMed files every randomised trial as a clinical trial too. They measure how much research exists — not whether this works or is safe for you.

Research (12)

Turn CBD into a plan that's yours

The info above is free. Membership makes it personal, the Coach answers questions about your exact stack, the Stack tracks it for you, and the Verified Sources shows you how to vet what you buy.

  • ✓ AI Coach, ask anything about your stack. It does the dosing math, flags interactions, and tells you what to do next.
  • ✓ Personal Stack, save your protocol, track it across devices, log doses, get a heads-up before a vial runs out.
  • ✓ Verified Sources, the vetted reference for checking quality and sourcing, members only.
Become a member, from $4.99/week

Cancel anytime · or save with $59.99/yr · Coach + Stack included

Where next

Every compound in the catalogThe full non-peptide index, with evidence grades.→The peptide indexInjectable peptides, half-lives and what trials used.→Spotting a scam vendorRed flags, COA checks and what traceability looks like.→